Overcoming Drug Interference in Transfusion Testing: A Spotlight on Daratumumab

References

• Fung MG, Hillyer BJ. AABB Technical Manual. 18th ed. AABB; 2014.
   Google Scholar
• Pietsch EC, Dong J, Cardoso R, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. 2017;7(2):e536. doi:10.1038/bcj.2017.7
   PubMed Web of Science ®Google Scholar
• Tong B, Wang M. CD47 is a novel potent immunotherapy target in human malignancies: current studies and future promises. Future Oncol. 2018;14(21):2179–2188. doi:10.2217/fon-2018-0035
   PubMed Web of Science ®Google Scholar
• Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375(8):754–766. doi:10.1056/NEJMoa1606038
   PubMed Web of Science ®Google Scholar
• Kaufman GP, Schrier SL, Lafayette RA, Arai S, Witteles RM, Liedtke M. Daratumumab yields rapid and deep hematologic responses in patients with heavily pretreated AL amyloidosis. Blood. 2017;130(7):900–902. doi:10.1182/blood-2017-01-763599
   PubMed Web of Science ®Google Scholar
• Cancer Facts & Figures 2021. American Cancer Society journal, CA: a cancer journal for clinicians. Available from: https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2021.html. Accessed May 3, 2021.
   Google Scholar
• Plesner T, Arkenau HT, Gimsing P, et al. Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma. Blood. 2016;128(14):1821–1828. doi:10.1182/blood-2016-07-726729
   PubMed Web of Science ®Google Scholar
• Albeniz I, Demir Ö, Turker-Sener L, Yalcintepe L, Nurten R, Bermek E. Erythrocyte CD38 as a prognostic marker in cancer. Hematology. 2007;12(5):409–414. doi:10.1080/10245330701383841
   PubMed Web of Science ®Google Scholar
• de Weers M, Tai YT, van der Veer MS, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186(3):1840–1848. doi:10.4049/jimmunol.1003032
   PubMed Web of Science ®Google Scholar
• McKeage K. Daratumumab: first global approval. Drugs. 2016;76(2):275–281. doi:10.1007/s40265-015-0536-1
   PubMed Web of Science ®Google Scholar
• Clark CA, Cornell RF, Scott EC, Chung J, Costa LJ. Management of relapsed and refractory multiple myeloma in modern times: incorporating new agents into decision-making. Am J Hematol. 2016;91(10):1044–1051. doi:10.1002/ajh.24478
   Web of Science ®Google Scholar
• Darzalex package insert. Horsham, PA: Janssen Biotech; 2015. Available from: http://wwwdarzalexcom/shared/product/darzalex/darzalex-prescribing-informationpdf. Accessed March 3, 2021.
   Google Scholar
• Chapuy CI, Kaufman RM, Alyea EP, Connors JM. Daratumumab for delayed red-cell engraftment after allogeneic transplantation. N Engl J Med. 2018;379(19):1846–1850. doi:10.1056/NEJMoa1807438
   Web of Science ®Google Scholar
• Mirgh S, Ahmed R, Agrawal N, et al. Will daratumumab be the next game changer in early thymic precursor-acute lymphoblastic leukaemia? Br J Haematol. 2019;187(2):e33–e35. doi:10.1111/bjh.16154
   PubMed Web of Science ®Google Scholar
• van de Donk N, Richardson PG, Malavasi F. CD38 antibodies in multiple myeloma: back to the future. Blood. 2017;131(1):13–29. doi:10.1182/blood-2017-06-740944
   Web of Science ®Google Scholar
• Sullivan HC, Gerner-Smidt C, Nooka AK, et al. Daratumumab (anti-CD38) induces loss of CD38 on red blood cells. Blood. 2017;129(22):3033–3037. doi:10.1182/blood-2016-11-749432
   PubMed Web of Science ®Google Scholar
• Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk; 2017.
   Web of Science ®Google Scholar
• Schuetz C, Hoenig M, Moshous D, et al. Daratumumab in life-threatening autoimmune hemolytic anemia following hematopoietic stem cell transplantation. Blood Adv. 2018;2(19):2550–2553. doi:10.1182/bloodadvances.2018020883
   PubMed Web of Science ®Google Scholar
• Murphy MF, Dumont LJ, Greinacher A. Interference of new drugs with compatibility testing for blood transfusion. N Engl J Med. 2016;375(3):295–296. doi:10.1056/NEJMc1515969
   Web of Science ®Google Scholar
• Oostendorp M, Lammerts van Bueren JJ, Doshi P, et al. When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy. Transfusion. 2015;55(6 Pt 2):1555–1562. doi:10.1111/trf.13150
   PubMed Web of Science ®Google Scholar
• Vidal-Crespo A, Matas-Céspedes A, Rodriguez V, et al. Daratumumab displays in vitro and in vivo anti-tumor activity in models of B-cell non-Hodgkin lymphoma and improves responses to standard chemo-immunotherapy regimens. Haematologica. 2020;105(4):1032–1041. doi:10.3324/haematol.2018.211904
   PubMed Web of Science ®Google Scholar
• Salles G, Gopal AK, Minnema MC, et al. Phase 2 study of daratumumab in relapsed/refractory mantle-cell lymphoma, diffuse large B-cell lymphoma, and follicular lymphoma. Clin Lymphoma Myeloma Leuk. 2019;19(5):275–284. doi:10.1016/j.clml.2018.12.013
   PubMed Web of Science ®Google Scholar
• Berthelier V, Laboureau J, Boulla G, Schuber F, Deterre P. Probing ligand-induced conformational changes of human CD38. Eur J Biochem. 2000;267(10):3056–3064. doi:10.1046/j.1432-1033.2000.01329.x
   PubMedGoogle Scholar
• Anani WQ, Duffer K, Kaufman RM, Denomme GA. How do I work up pretransfusion samples containing anti-CD38? Transfusion. 2017;57(6):1337–1342. doi:10.1111/trf.14144
   PubMed Web of Science ®Google Scholar
• Chapuy CI, Nicholson RT, Aguad MD, et al. Resolving the daratumumab interference with blood compatibility testing. Transfusion. 2015;55(6 Pt 2):1545–1554. doi:10.1111/trf.13069
   PubMed Web of Science ®Google Scholar
• M L-fc R, Olsson ML. The Blood Group Antigen Factsbook. 3rd ed. MA: Academic Press; 2012.
   Google Scholar
• Chapuy CI, Aguad MD, Nicholson RT, et al. International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing. Transfusion. 2016;56(12):2964–2972. doi:10.1111/trf.13789
   PubMed Web of Science ®Google Scholar
• Hosokawa M, Kashiwagi H, Nakayama K, et al. Distinct effects of daratumumab on indirect and direct antiglobulin tests: a new method employing 0.01 mol/L dithiothreitol for negating the daratumumab interference with preserving K antigenicity (Osaka method). Transfusion. 2018;58(12):3003–3013. doi:10.1111/trf.14900
   PubMed Web of Science ®Google Scholar
• Hosokawa M, Kashiwagi H, Nakayama K, et al. Additional validation of Osaka method (0.01 mol/L dithiothreitol) for negating the daratumumab interference. Transfusion. 2019;59(7):2479–2480. doi:10.1111/trf.15305
   Web of Science ®Google Scholar
• Disbro WL. Stability guidelines for dithiothreitol-treated red blood cell reagents used for antibody detection methods in patients treated with daratumumab. Immunohematology. 2017;33(3):105–109. doi:10.21307/immunohematology-2019-015
   Google Scholar
• Lancman G, Arinsburg S, Jhang J, et al. Blood transfusion management for patients treated with anti-cd38 monoclonal antibodies. Front Immunol. 2018;9:2616. doi:10.3389/fimmu.2018.02616
   PubMed Web of Science ®Google Scholar
• Bub CB, Reis IND, Aravechia MG, et al. Transfusion management for patients taking an anti-CD38 monoclonal antibody. Rev Bras Hematol Hemoter. 2018;40(1):25–29. doi:10.1016/j.bjhh.2017.09.003
   Google Scholar
• Yeh TJ, Yeh CJ, Liu YC, Hsiao HH. Manual polybrene method for pretransfusion test could overcome the interference of daratumumab therapy in myeloma. Transfusion. 2019;59(8):2751–2752. doi:10.1111/trf.15341
   Web of Science ®Google Scholar
• Schmidt AE, Kirkley S, Patel N, et al. An alternative method to dithiothreitol treatment for antibody screening in patients receiving daratumumab. Transfusion. 2015;55(9):2292–2293. doi:10.1111/trf.13174
   PubMed Web of Science ®Google Scholar
• De Vooght KM, Oostendorp M, van Solinge WW. Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing. Transfusion. 2016;56(3):778–779. doi:10.1111/trf.13474
   Web of Science ®Google Scholar
• Quach H, Benson S, Haysom H, et al. Considerations for pre-transfusion immunohaematology testing in patients receiving the anti-CD38 monoclonal antibody daratumumab for the treatment of multiple myeloma. Intern Med J. 2018;48(2):210–220. doi:10.1111/imj.13707
   PubMed Web of Science ®Google Scholar
• Selleng K, Gebicka PD, Thiele TF. (ab’)2 fragments to overcome daratumumab interference in transfusion tests. N Engl J Med. 2018;379(1):90–91. doi:10.1056/NEJMc1804751
   PubMed Web of Science ®Google Scholar
• Chinoca Ziza KN, Paiva TA, Mota SR, et al. A blockage monoclonal antibody protocol as an alternative strategy to avoid anti-CD38 interference in immunohematological testing. Transfusion. 2019;59(5):1827–1835. doi:10.1111/trf.15202
   Web of Science ®Google Scholar
• Baig NA, Dukek BA, Falbo DK, et al. Daratumumab interference in flow cytometric anti-granulocyte antibody testing can be overcome using non-human blocking antibodies. Vox Sang. 2021;116(1):116–122. doi:10.1111/vox.12989
   Web of Science ®Google Scholar
• Tremblay T, Branch DR, Loubaki L. Daudi cell stroma: an alternative to dithiothreitol to resolve daratumumab interference in pretransfusion testing. Transfusion. 2020;60(9):2090–2096. doi:10.1111/trf.15932
   Web of Science ®Google Scholar
• Tapia-Alveal C, Olsen TR, Worgall TS. Personalized immunoglobulin aptamers for detection of multiple myeloma minimal residual disease in serum. Commun Biol. 2020;3(1):781. doi:10.1038/s42003-020-01515-x
   Web of Science ®Google Scholar
• Hannon JL, Clarke G. Transfusion management of patients receiving daratumumab therapy for advanced plasma cell myeloma. Transfusion. 2015;55(11):2770. doi:10.1111/trf.13267
   Web of Science ®Google Scholar
• Mitigating the anti-CD38 interference with serologic testing AABB association bulletin #16-02; 2016. Available from: http://www.aabb.org/programs/publications/bulletins/Documents/ab16-02.pdf. Accessed May 3, 2021.
   Google Scholar
• Chari A, Arinsburg S, Jagannath S, et al. Blood transfusion management and transfusion-related outcomes in daratumumab-treated patients with relapsed or refractory multiple myeloma. Clin Lymphoma Myeloma Leuk. 2018;18(1):44–51. doi:10.1016/j.clml.2017.09.002
   PubMed Web of Science ®Google Scholar
• Ye Z, Wolf LA, Mettman D, Plapp FV. Risk of RBC alloimmunization in multiple myeloma patients treated by daratumumab. Vox Sang. 2020;115(2):207–212. doi:10.1111/vox.12864
   PubMed Web of Science ®Google Scholar
• Anani WQ, Marchan MG, Bensing KM, et al. Practical approaches and costs for provisioning safe transfusions during anti-CD38 therapy. Transfusion. 2017;57(6):1470–1479. doi:10.1111/trf.14021
   Web of Science ®Google Scholar
• Cushing MM, DeSimone RA, Goel R, et al. The impact of daratumumab on transfusion service costs. Transfusion. 2019;59(4):1252–1258. doi:10.1111/trf.15134
   Web of Science ®Google Scholar
• Setia R, Dogra M, Sachdeva P, Handoo A, Choudhary D, Agarwal A. Daratumumab (Anti-CD38) interference with serological testing: an emerging challenge for blood banks in developing countries. Glob J Transfus Med. 2017;2(2):163. doi:10.4103/GJTM.GJTM_42_17
   Google Scholar